AU2005287799B2 - Pharmaceutical composition comprising temozolomide ester - Google Patents

Pharmaceutical composition comprising temozolomide ester Download PDF

Info

Publication number
AU2005287799B2
AU2005287799B2 AU2005287799A AU2005287799A AU2005287799B2 AU 2005287799 B2 AU2005287799 B2 AU 2005287799B2 AU 2005287799 A AU2005287799 A AU 2005287799A AU 2005287799 A AU2005287799 A AU 2005287799A AU 2005287799 B2 AU2005287799 B2 AU 2005287799B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
carboxylate
tmz
methyl
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005287799A
Other languages
English (en)
Other versions
AU2005287799A1 (en
Inventor
Yongfeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Tasly Diyi Pharmaceutical Co Ltd
Original Assignee
TASLY HOLDING GROUP CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TASLY HOLDING GROUP CO Ltd filed Critical TASLY HOLDING GROUP CO Ltd
Publication of AU2005287799A1 publication Critical patent/AU2005287799A1/en
Application granted granted Critical
Publication of AU2005287799B2 publication Critical patent/AU2005287799B2/en
Assigned to TASLY HOLDING GROUP CO., LTD. reassignment TASLY HOLDING GROUP CO., LTD. Request to Amend Deed and Register Assignors: TIAN JIN TASLY GROUP CO., LTD.
Assigned to JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. reassignment JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: TASLY HOLDING GROUP CO., LTD.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005287799A 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester Ceased AU2005287799B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410072056.4 2004-09-22
CNA2004100720564A CN1752088A (zh) 2004-09-22 2004-09-22 含有替莫唑胺酯的药用组合物
PCT/CN2005/001477 WO2006032190A1 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester

Publications (2)

Publication Number Publication Date
AU2005287799A1 AU2005287799A1 (en) 2006-03-30
AU2005287799B2 true AU2005287799B2 (en) 2009-03-26

Family

ID=36089840

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005287799A Ceased AU2005287799B2 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester

Country Status (20)

Country Link
US (1) US7579336B2 (https=)
EP (1) EP1798234B1 (https=)
JP (2) JP5620046B2 (https=)
KR (1) KR101065984B1 (https=)
CN (1) CN1752088A (https=)
AR (1) AR050947A1 (https=)
AU (1) AU2005287799B2 (https=)
BR (1) BRPI0515555A (https=)
CA (1) CA2580910C (https=)
DK (1) DK1798234T3 (https=)
ES (1) ES2389376T3 (https=)
IL (1) IL182027A (https=)
MX (1) MX2007003366A (https=)
MY (1) MY153713A (https=)
NZ (1) NZ554609A (https=)
PL (1) PL1798234T3 (https=)
RU (1) RU2393160C2 (https=)
UA (1) UA89795C2 (https=)
WO (1) WO2006032190A1 (https=)
ZA (1) ZA200702801B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1727340B (zh) * 2004-07-29 2011-05-18 天津帝士力投资控股集团有限公司 一种替莫唑胺-8-羧酸酯及其组合物
EP1808173A1 (en) * 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
US8558511B2 (en) * 2009-04-07 2013-10-15 Battelle Memorial Institute Method and apparatus for smart battery charging including a plurality of controllers each monitoring input variables
KR20140087846A (ko) * 2012-12-31 2014-07-09 주식회사 삼양바이오팜 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
RU2527258C1 (ru) * 2013-02-19 2014-08-27 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
US10709715B2 (en) * 2017-12-03 2020-07-14 Cipla Limited Method of treating hypertension
EP3833342A4 (en) * 2018-08-09 2022-07-13 The Board of Trustees of the University of Illinois IMIDAZOTETRAZINE COMPOUNDS
CN114014862A (zh) * 2021-06-28 2022-02-08 烟台大学 一种治疗脑胶质瘤的新化合物及其制备和应用
CN116947765B (zh) * 2022-06-23 2025-10-10 北京新源医疗有限责任公司 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1485327A (zh) * 2002-09-29 2004-03-31 天津天士力集团有限公司 替莫唑胺-8-羧酸脂和-8-酰胺衍生物，它们的合成方法以及它们在制备抗癌制剂中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616125D0 (en) * 1986-07-02 1986-08-06 May & Baker Ltd Compositions of matter
UA29466C2 (uk) * 1993-01-14 2000-11-15 Канзер Рісерч Кампейн Технолоджі, Лтд Фармацевтична композиція з антипухлинною активністю
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1485327A (zh) * 2002-09-29 2004-03-31 天津天士力集团有限公司 替莫唑胺-8-羧酸脂和-8-酰胺衍生物，它们的合成方法以及它们在制备抗癌制剂中的应用

Also Published As

Publication number Publication date
CA2580910C (en) 2011-10-25
UA89795C2 (ru) 2010-03-10
EP1798234A1 (en) 2007-06-20
CN1752088A (zh) 2006-03-29
US20080044457A1 (en) 2008-02-21
EP1798234A4 (en) 2009-04-29
JP2013028630A (ja) 2013-02-07
ZA200702801B (en) 2008-08-27
BRPI0515555A (pt) 2008-07-29
MX2007003366A (es) 2008-03-05
AR050947A1 (es) 2006-12-06
PL1798234T3 (pl) 2012-11-30
US7579336B2 (en) 2009-08-25
KR101065984B1 (ko) 2011-09-19
HK1100440A1 (en) 2007-09-21
AU2005287799A1 (en) 2006-03-30
NZ554609A (en) 2010-06-25
DK1798234T3 (da) 2012-08-27
CA2580910A1 (en) 2006-03-30
KR20070062569A (ko) 2007-06-15
JP2008513523A (ja) 2008-05-01
JP5620046B2 (ja) 2014-11-05
IL182027A0 (en) 2007-07-24
ES2389376T3 (es) 2012-10-25
MY153713A (en) 2015-03-13
WO2006032190A1 (en) 2006-03-30
RU2393160C2 (ru) 2010-06-27
RU2007114948A (ru) 2008-10-27
IL182027A (en) 2014-05-28
EP1798234B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
CN119585286A (zh) 吡啶并[4,3-d]嘧啶化合物
IL182027A (en) Pharmaceutical composition comprising tamoxolomide ester and the method of preparation thereof
US9233976B2 (en) Berbamine derivatives
KR19990008051A (ko) 라디시콜 유도체
US12391706B2 (en) Multi-target tyrosine kinase inhibitor
CN114450278B (zh) 一个烟醇醚衍生物的马来酸盐及其晶型和应用
AU2019379797B2 (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
CN101863901A (zh) 2-(取代苯基)-2-(4,5,6,7-四氢噻吩并[3,2-c]吡啶-5(4H)-基)-N-取代-乙酰胺、其制备方法和用途
CN115894607B (zh) 一种抗肿瘤的苯丙氨酸缬氨酰衍生物及其制备方法
EP2452681B1 (en) SALTS OF 13a-(S)-DEOXYTYLOPHORININE, PREPARATION METHODS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
Wang et al. Synthesis and evaluation of an injectable everolimus prodrug
HK1100440B (en) Pharmaceutical composition comprising temozolomide ester
US9499552B2 (en) Pyrazolo[1,5-A]pyrimidine derivative and use of anti-tumor thereof
CN101885726B (zh) 化合物结构及制备方法与用途
WO2020254484A1 (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
CN114409669B (zh) 一种氧杂降冰片烯环上c-5位炔基取代的斑蝥素衍生物及其制备方法与应用
CN101845052A (zh) 一类含氮杂环的噻吩并吡啶酮衍生物、其制备方法和用途
WO2002088137A9 (en) Pkb-3564 substance with neovascularization inhibitory activity
CN120817954A (zh) 喜树碱与柠檬酸共晶及制备方法和其组合物与用途
CN107163047A (zh) 槐定胺类衍生物及其制备方法和用途
WO2024189647A1 (en) Cocrystal of telmisartan and ascorbic acid, composition comprising same and method of use
TW202116778A (zh) 作為治療劑之細胞毒素之肽結合物
CN1727340A (zh) 一种替莫唑胺－8－羧酸酯及其组合物
CN110117280A (zh) (13aS)-3-新戊酰氧基-6,7-二甲氧基菲并吲哚里西啶的晶A型
WO2016161538A1 (zh) 3-酰氧基取代右旋去氧娃儿藤宁衍生物、其制法和药物组合物与用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER(S): TASLY HOLDING GROUP CO., LTD.

Owner name: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER WAS: TASLY HOLDING GROUP CO., LTD.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired